Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/29/2023 | $6.00 | Outperform | RBC Capital Mkts |
4/21/2023 | $8.00 | Buy | The Benchmark Company |
4/13/2023 | $10.00 | Buy | Craig Hallum |
2/22/2023 | $10.00 | Outperform | Cowen |
2/13/2023 | $11.00 | Buy | H.C. Wainwright |
4 - OmniAb, Inc. (0001846253) (Issuer)
3 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Thursday, May 8, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss first quarter 2025 financial results and business updates Date: Thursday, May 8, 2025 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Phone: U.S. (800) 549 8228 International (289) 819 1520 Conference ID is 96760
Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates. "2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs. Clinical-stage programs advanced well, and we launched new technologies and enhancements that strengthened our platform and expanded our reach," said Matt Foehr, Chief Executive Officer of OmniAb. "We exceeded our internal goals for key metrics and continued to build momentum while optimizing the scalability of our business. We believe our co
OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Tuesday, March 18, 2025 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss fourth quarter financial results and business updates Date: Tuesday, March 18, 2025 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Phone: U.S. (800) 549 8228 International (289) 819 1520 Conference ID is 84579
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
4 - OmniAb, Inc. (0001846253) (Issuer)
Philip Gotwals, Ph.D. and Steve Crouse bring strategic and operational experience in business development and global tools and technology OmniAb, Inc. (NASDAQ:OABI) today announced the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. OmniAb also announced the departure of Director Sarah Boyce, who is stepping down following nearly six years of service during a period of key strategic acquisitions and the significant expansion of the scope and size of OmniAb's partnership base. These Board changes are effective immediately and increase the number of Directors to seven. "We're delighted to welcome Phil and Steve to our Board of Directors. Their extensive
OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Thursday, May 8, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What: OmniAb conference call to discuss first quarter 2025 financial results and business updates Date: Thursday, May 8, 2025 Time: 4:30 p.m. Eastern time (1:30 p.m. Pacific time) Phone: U.S. (800) 549 8228 International (289) 819 1520 Conference ID is 96760
Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates. "2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs. Clinical-stage programs advanced well, and we launched new technologies and enhancements that strengthened our platform and expanded our reach," said Matt Foehr, Chief Executive Officer of OmniAb. "We exceeded our internal goals for key metrics and continued to build momentum while optimizing the scalability of our business. We believe our co
SC 13G/A - OmniAb, Inc. (0001846253) (Subject)
SC 13D/A - OmniAb, Inc. (0001846253) (Subject)
8-K - OmniAb, Inc. (0001846253) (Filer)
144 - OmniAb, Inc. (0001846253) (Subject)
144 - OmniAb, Inc. (0001846253) (Subject)
RBC Capital Mkts initiated coverage of OmniAb with a rating of Outperform and set a new price target of $6.00
The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00
Craig Hallum initiated coverage of OmniAb with a rating of Buy and set a new price target of $10.00
OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our